Quick Answer
Aclaris Therapeutics, Inc. reported Stockholders Equity of $103.08 million for the year ending 2025.
- Aclaris Therapeutics, Inc. showed a decrease of -33.7% in Stockholders Equity from 2024 to 2025.
- This data is from Aclaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $83.21 million | Q2 2016: $90.24 million | Q3 2016: $81.12 million | Q1 2017: $160.29 million | Q2 2017: $168.14 million | Q3 2017: $244.26 million | Q1 2018: $200.47 million | Q2 2018: $174.20 million | Q3 2018: $146.33 million | Q1 2019: $182.25 million | Q2 2019: $137.23 million | Q3 2019: $85.28 million | Q1 2020: $58.15 million | Q2 2020: $49.37 million | Q3 2020: $40.76 million | Q1 2021: $112.29 million | Q2 2021: $233.82 million | Q3 2021: $216.58 million | Q1 2022: $180.20 million | Q2 2022: $235.75 million | Q3 2022: $219.84 million | Q1 2023: $176.81 million | Q2 2023: $179.75 million | Q3 2023: $156.33 million | Q1 2024: $142.01 million | Q2 2024: $133.82 million | Q3 2024: $130.15 million | Q1 2025: $144.07 million | Q2 2025: $131.74 million | Q3 2025: $120.10 million.
- Over the full 14 years of available data (2012 to 2025), Aclaris Therapeutics, Inc.'s Stockholders Equity has grown by 4,806.9%.
- Historical annual values: Fiscal year 2025: $103.08 million | Fiscal year 2024: $155.55 million | Fiscal year 2023: $157.18 million | Fiscal year 2022: $197.62 million | Fiscal year 2021: $197.34 million | Fiscal year 2020: $37.65 million | Fiscal year 2019: $69.91 million | Fiscal year 2018: $215.12 million | Fiscal year 2017: $225.26 million | Fiscal year 2016: $169.49 million | Fiscal year 2015: $92.52 million | Fiscal year 2014: -$20.76 million | Fiscal year 2013: -$9.16 million | Fiscal year 2012: -$2.19 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: